睿知中国医院研究地图
候选清单

正在招募肺癌II期

登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)

JS212 Plus JS111 in EGFR-Mutant Advanced NSCLC: A Phase II Study

ClinicalTrials.gov 上登记的一项肺癌开放试验。牵头方不是本站收录的医院;本站收录的 1 家医院列为研究中心。

状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月18日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。

研究团队的联系方式见登记记录。本站不转递咨询。

列出这项试验的中国大陆医院 1

登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。

  1. 研究中心上海市胸科医院Shanghai Chest Hospital上海医院页面

登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心

来源:ClinicalTrials.gov 登记记录 NCT07518160,读取于 2026年11月18日;医院名称与本站医院名单匹配。 名称如何匹配

这项试验的核对清单 8

只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。

展开清单(8 项)收起清单
  1. 18 岁 至 75 岁;性别:不限

    登记记录的入选字段

  2. Histologically or cytologically confirmed recurrent or metastatic non-squamous NSCLC that is unresectable and not amenable to curative chemoradiotherapy;

    入选标准第 2 条

  3. Within: 4 weeks or 5 half-lives (whichever is shorter) prior to first dose: chemotherapy or similar therapies;7 days: small molecule targeted therapy; 2 weeks: localized radiotherapy (e.g., palliative radiation for bone metastases);

    排除标准第 3 条

  4. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1;

    入选标准第 6 条

  5. Absolute neutrophil count ≥1.5 × 10⁹/L;

    入选标准第 9 条

    Platelet count ≥100 × 10⁹/L;

    入选标准第 10 条

    Hemoglobin ≥90 g/L (≥9 g/dL);

    入选标准第 11 条

    ALT and AST ≤2.5 × ULN (≤5 × ULN in case of liver metastases);

    入选标准第 12 条

    Total bilirubin ≤1.5 × ULN;

    入选标准第 13 条

    Creatinine clearance ≥50 mL/min (calculated by Cockcroft-Gault formula);

    入选标准第 14 条

    Activated partial thromboplastin time (APTT) ≤1.5 × ULN and international normalized ratio (INR) ≤1.5(patients on stable anticoagulant therapy such as low molecular weight heparin or warfarin are allowed if INR is within the therapeutic range);

    入选标准第 15 条

  6. At least one measurable lesion per RECIST v1.1;

    入选标准第 5 条

  7. Immunodeficiency History of immunodeficiency, including HIV positivity;Other acquired or congenital immunodeficiency;History of organ transplantation, allogeneic bone marrow transplantation, or autologous hematopoietic stem cell transplantation;

    排除标准第 20 条

    Viral hepatitis Active HBV infection: HBsAg positive with HBV DNA ≥1000 copies/mL or ≥200 IU/mL; Active HCV infection: HCV antibody positive with detectable HCV RNA above LLOQ;

    排除标准第 22 条

    Other malignancies Any other malignancy requiring treatment within 5 years prior to first dose, except: Malignancies with low metastatic risk and >90% 5-year survival, such as: Adequately treated basal or squamous cell skin cancer, Carcinoma in situ of cervix or breast, Localized prostate cancer, Papillary thyroid carcinoma;

    排除标准第 23 条

  8. Non-sterilized male participants who are sexually active with women of childbearing potential must: Agree to use effective contraception as described in Section 10.3.2 from signing the ICF until 4 months after the last dose of JS212 or JS111, and Refrain from sperm donation during this period;

    入选标准第 17 条

    Pregnancy and lactation Pregnant or breastfeeding women, or those planning pregnancy during the study;

    排除标准第 24 条

勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:分期或严重程度(按试验的定义)。

需要向研究团队确认的问题

按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT07518160,读取于 2026年11月10日。

登记的入选标准

依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。

入选标准:Inclusion Criteria:

  1. Age between 18 and 75 years (inclusive) at the time of signing the informed consent form (ICF), regardless of sex;
  2. Histologically or cytologically confirmed recurrent or metastatic non-squamous NSCLC that is unresectable and not amenable to curative chemoradiotherapy;
  3. Confirmed EGFR-sensitizing mutation, including:
  4. Prior treatment with:
  5. At least one measurable lesion per RECIST v1.1;
  6. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1;
  7. Estimated life expectancy of ≥12 weeks;
  8. Adequate organ function meeting the following criteria (Note: No blood transfusion or hematopoietic growth factors are allowed within 14 days prior to screening assessments):
  9. Absolute neutrophil count ≥1.5 × 10⁹/L;
  10. Platelet count ≥100 × 10⁹/L;
  11. Hemoglobin ≥90 g/L (≥9 g/dL);
  12. ALT and AST ≤2.5 × ULN (≤5 × ULN in case of liver metastases);
  13. Total bilirubin ≤1.5 × ULN;
  14. Creatinine clearance ≥50 mL/min (calculated by Cockcroft-Gault formula);
  15. Activated partial thromboplastin time (APTT) ≤1.5 × ULN and international normalized ratio (INR) ≤1.5(patients on stable anticoagulant therapy such as low molecular weight heparin or warfarin are allowed if INR is within the therapeutic range);
  16. Female participants of childbearing potential (WOCBP) who are sexually active with non-sterilized male partners must:
  17. Non-sterilized male participants who are sexually active with women of childbearing potential must: Agree to use effective contraception as described in Section 10.3.2 from signing the ICF until 4 months after the last dose of JS212 or JS111, and Refrain from sperm donation during this period;
  18. Participants must voluntarily participate in this study and provide written informed consent.

排除标准:Exclusion Criteria:

  1. Disease-related conditions:
  2. Prior/concomitant treatments:
  3. Within: 4 weeks or 5 half-lives (whichever is shorter) prior to first dose: chemotherapy or similar therapies;7 days: small molecule targeted therapy; 2 weeks: localized radiotherapy (e.g., palliative radiation for bone metastases);
  4. Use of strong CYP3A inhibitors or inducers within 14 days prior to first dose or requirement for continued use during study;
  5. Current use or requirement for use of medications known to prolong QT interval or cause torsades de pointes;
  6. Receipt of any investigational drug within 4 weeks or 5 half-lives prior to first dose (whichever is shorter);
  7. Participation in another clinical trial, unless it is: Observational (non-interventional), or The participant is in the follow-up phase of an interventional study;
  8. Major surgery (e.g., craniotomy, thoracotomy, laparotomy) within 4 weeks prior to first dose;
  9. Toxicity Unresolved toxicities from prior anti-tumor therapy that have not recovered to:
  10. Hypersensitivity Known allergy or hypersensitivity to any study drug or its excipients;
  11. Cardiac conditions:
  12. QTcF:≥450 ms (male), ≥470 ms (female), averaged from 3 ECG measurements;
  13. Clinically significant arrhythmias, including but not limited to:Complete left bundle branch block,Third-degree AV block,Second-degree AV block,PR interval >250 ms;
  14. Risk factors for torsades de pointes, such as: Clinically significant hypokalemia,Family history of long QT syndrome or arrhythmias;
  15. Left ventricular ejection fraction (LVEF) <50%;
  16. Gastrointestinal conditions Conditions affecting drug absorption, distribution, metabolism, or excretion, such as: Inability to swallow oral medication, Persistent vomiting,Uncontrolled diarrhea,Extensive gastrointestinal resection,Crohn's disease, ulcerative colitis;
  17. Pulmonary conditions History of or suspected: Interstitial lung disease, Drug-induced pneumonitis,Idiopathic pneumonitis,Idiopathic pulmonary fibrosis,or other significant pulmonary disease (≤Grade 1 radiation pneumonitis is allowed);
  18. Ocular conditions Severe or uncontrolled ocular disorders that may increase risk, including:
  19. Infection Severe infection (CTCAE ≥ Grade 3) within 4 weeks prior to first dose; Evidence of active pulmonary inflammation on imaging at baseline; Infection requiring systemic antibiotics within 2 weeks prior to first dose (excluding prophylactic use);
  20. Immunodeficiency History of immunodeficiency, including HIV positivity;Other acquired or congenital immunodeficiency;History of organ transplantation, allogeneic bone marrow transplantation, or autologous hematopoietic stem cell transplantation;
  21. Tuberculosis Active tuberculosis, or History of active tuberculosis within 1 year prior to enrollment, or History of active tuberculosis >1 year ago without adequate treatment;
  22. Viral hepatitis Active HBV infection: HBsAg positive with HBV DNA ≥1000 copies/mL or ≥200 IU/mL; Active HCV infection: HCV antibody positive with detectable HCV RNA above LLOQ;
  23. Other malignancies Any other malignancy requiring treatment within 5 years prior to first dose, except: Malignancies with low metastatic risk and >90% 5-year survival, such as: Adequately treated basal or squamous cell skin cancer, Carcinoma in situ of cervix or breast, Localized prostate cancer, Papillary thyroid carcinoma;
  24. Pregnancy and lactation Pregnant or breastfeeding women, or those planning pregnancy during the study;
  25. Uncontrolled comorbidities Including but not limited to: Symptomatic congestive heart failure within 6 months, Uncontrolled hypertension, Unstable angina, Uncontrolled arrhythmia, Major seizure disorders,Superior vena cava syndrome,Aortic aneurysm requiring surgery, Arterial thromboembolism,≥Grade 3 venous thromboembolism (CTCAE v6.0),Stroke or transient ischemic attack; or psychiatric/social conditions that may affect compliance or informed consent;
  26. Investigator judgment Any condition that, in the investigator's opinion, may: Lead to premature discontinuation,Compromise patient safety, or Affect data integrity, including abnormal laboratory values or unfavorable social/family circumstances.

引自 ClinicalTrials.gov, NCT07518160, 参与标准,读取于 2026年11月10日。

这些信息从哪里来

登记记录

ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT07518160,读取于 2026年11月18日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。

疾病与医院

本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义

没有收录的内容

登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。

提出更正ClinicalTrials.gov NCT07518160